Efficacy of azithromycin in preventing lethal graft-versus-host disease

Clinical and Experimental Immunology

Volumn 171, Issue 3, 2013, Pages 338-345

  Iwamoto, S ^a   Azuma, E ^a   Kumamoto, T ^a   Hirayama, M ^a   Yoshida, T ^a   Ito, M ^a   Amano, K ^a   Ido, M ^b   Komada, Y ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Azithromycin; Dendritic cells; Graft versus host disease; Nuclear factor (NF) B; Transplantation

Indexed keywords

AZITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DENDRITIC CELLS; FEMALE; GRAFT VS HOST DISEASE; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NF-KAPPA B;

EID: 84873296468     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12023     Document Type: Article

References (57)

1. Choi SW, Hildebrandt GC, Olkiewicz KM etal. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood 2007; 110:3447-3455.
2. Drobyski WR, Majewski D. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Blood 1996; 87:5355-5369.
3. Stuehler C, Mielke S, Chatterjee M etal. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 2009; 114:2829-2836.
4. Park HB, Oh K, Garmaa N etal. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway. Transplantation 2010; 90:825-835.
5. Ranganathan P, Heaphy CE, Costinean S etal. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012; 119:4786-4797.
6. Shlomchik WD, Couzens MS, Tang CB etal. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412-415.
7. Teshima T, Ordemann R, Reddy P etal. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8:575-581.
8. Duffner UA, Maeda Y, Cooke KR etal. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172:7393-7398.
9. Matte CC, Liu J, Cormier J etal. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10:987-992.
10. Taylor PA, Ehrhardt MJ, Lees CJ etal. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007; 110:3480-3488.
11. Koyama M, Hashimoto D, Aoyama K etal. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood 2009; 113:2088-2095.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
13. Banchereau J, Briere F, Caux C etal. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
14. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388:782-787.
15. Stenger EO, Turnquist HR, Mapara MY, Thomson AW. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012; 119:5088-5103.
16. Falvo JV, Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995; 80:529-532.
17. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9:2723-2735.
18. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001; 13:675-683.
19. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998; 188:2175-2180.
20. Sun K, Wilkins DE, Anver MR etal. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005; 106:3293-3299.
21. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006; 107:827-834.
22. Tao Y, Zhang W, Fang Y etal. Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells. Exp Hematol 2011; 39:710-720.
23. Koreth J, Stevenson KE, Kim HT etal. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009; 114:3956-3959.
24. Iwamoto S, Kumamoto T, Azuma E etal. The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells. Clin Exp Immunol 2011; 166:385-392.
25. Azuma E, Yamamoto H, Kaplan J. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease. J Immunol 1989; 143:1524-1529.
26. Cooke KR, Kobzik L, Martin TR etal. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88:3230-3239.
27. Hill GR, Cooke KR, Teshima T etal. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102:115-123.
28. Matta BM, Raimondi G, Rosborough BR, Sumpter TL, Thomson AW. IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J Immunol 2012; 188:5227-5237.
29. Umemoto M, Azuma E, Hirayama M etal. Cytokine-enhanced mixed lymphocyte reaction (MLR) in cord blood. Clin Exp Immunol 1998; 112:459-463.
30. Shlomchik WD, Couzens MS, Tang CB etal. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412-415.
31. MacDonald KP, Kuns RD, Rowe V etal. Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. Blood 2007; 109:5049-5057.
32. Cetkovic-Cvrlje M, Roers BA, Waurzniak B, Liu XP, Uckun FM. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98:1607-1613.
33. Merad M, Hoffmann P, Ranheim E etal. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10:510-517.
34. Sugerman PB, Faber SB, Willis LM etal. Kinetics of gene expression in murine cutaneous graft-versus-host disease. Am J Pathol 2004; 164:2189-2203.
35. Sugiyama K, Shirai R, Mukae H etal. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 2007; 147:540-546.
36. Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-132.
37. Yamauchi K, Shibata Y, Kimura T etal. Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages. Int J Biol Sci 2009; 5:667-678.
38. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003; 18:367-379.
39. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389-399.
40. O'Keeffe M, Hochrein H, Vremec D etal. Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1precursors. Blood 2003; 101:1453-1459.
41. Maraskovsky E, Brasel K, Teepe M etal. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184:1953-1962.
42. Masten BJ, Olson GK, Kusewitt DF, Lipscomb MF. Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol 2004; 172:4077-4083.
43. Shurin MR, Pandharipande PP, Zorina TD etal. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997; 179:174-184.
44. Tomazic J, Kotnik V, Wraber B. In vivo administration of azithromycin affects lymphocyte activity in vitro. Antimicrob Agents Chemother 1993; 37:1786-1789.
45. Ratanatharathorn V, Nash RA, Przepiorka D etal. Phase III study comparing methothrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-indentical sibling bone marrow transplantation. Blood 1998; 92:2303-2314.
46. Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:76-77.
47. Grayston JT, Kronmal RA, Jackson LA etal. Azythromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352:1637-1645.
48. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-1890.
49. Cooke KR, Gerbitz A, Crawford JM etal. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107:1581-1589.
50. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90:3204-3213.
51. Storb R, Prentice RL, Buckner CD etal. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308:302-307.
52. Guthery SL, Heubi JE, Filipovich A. Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: results of a pilot study. Bone Marrow Transplant 2004; 33:1235-1239.
53. Eriguchi Y, Takashima S, Oka H etal. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012; 120:223-231.
54. Jenq RR, Ubeda C, Taur Y etal. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209:903-911.
55. Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1, 500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999; 43:163-165.
56. Dumas JL, Chang R, Mermillod B, Piguet PF, Comte R, Pechère JC. Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother 1994; 34:111-118.
57. Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest 2002; 109:1335-1344.